RT Journal Article
T1 Circulating pyruvate is a potent prognostic marker for critical COVID-19 outcomes.
A1 Ceperuelo-Mallafre, Victoria
A1 Reverte, Laia
A1 Peraire, Joaquim
A1 Madeira, Ana
A1 Maymo-Masip, Elsa
A1 Lopez-Dupla, Miguel
A1 Gutierrez-Valencia, Alicia
A1 Ruiz-Mateos, Ezequiel
A1 Buzon, Maria Jose
A1 Jorba, Rosa
A1 Vendrell, Joan
A1 Auguet, Teresa
A1 Olona, Montserrat
A1 Vidal, Francesc
A1 Rull, Anna
A1 Fernandez-Veledo, Sonia
K1 COVID-19
K1 energy-related metabolites
K1 fluorometric quantification
K1 pyruvate
K1 semi-targeted metebolomics
AB Coronavirus-19 (COVID-19) disease is driven by an unchecked immune response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus which alters host mitochondrial-associated mechanisms. Compromised mitochondrial health results in abnormal reprogramming of glucose metabolism, which can disrupt extracellular signalling. We hypothesized that examining mitochondrial energy-related signalling metabolites implicated in host immune response to SARS-CoV-2 infection would provide potential biomarkers for predicting the risk of severe COVID-19 illness. We used a semi-targeted serum metabolomics approach in 273 patients with different severity grades of COVID-19 recruited at the acute phase of the infection to determine the relative abundance of tricarboxylic acid (Krebs) cycle-related metabolites with known extracellular signaling properties (pyruvate, lactate, succinate and α-ketoglutarate). Abundance levels of energy-related metabolites were evaluated in a validation cohort (n=398) using quantitative fluorimetric assays. Increased levels of four energy-related metabolites (pyruvate, lactate, a-ketoglutarate and succinate) were found in critically ill COVID-19 patients using semi-targeted and targeted approaches (p Our findings support the link between COVID-19 pathogenesis and immunometabolic dysregulation, and show that fluorometric quantification of circulating pyruvate is a cost-effective clinical decision support tool to improve patient stratification and prognosis prediction.
PB Frontiers Research Foundation
YR 2022
FD 2022-09-14
LK http://hdl.handle.net/10668/20589
UL http://hdl.handle.net/10668/20589
LA en
NO Ceperuelo-Mallafré V, Reverté L, Peraire J, Madeira A, Maymó-Masip E, López-Dupla M, et al. Circulating pyruvate is a potent prognostic marker for critical COVID-19 outcomes. Front Immunol. 2022 Sep 14;13:912579.
DS RISalud
RD Apr 12, 2025